Skip to main content
SpringerLink
Log in

Orale Antidiabetika

Oral antidiabetic drugs

  • Klinische Pharmakologie
  • Published:
Der Kardiologe Aims and scope

Zusammenfassung

Diabetes mellitus gehört zu den weltweit am stärksten zunehmenden Erkrankungen, wobei ca. 90–95% der Patienten an Diabetes Typ 2 erkranken. Diabetes Typ 2 wird durch eine periphere Insulinresistenz und einen zunehmenden Verlust der β-Zell-Funktion charakterisiert. Angesichts der Komplikationen insbesondere im Bereich kardiovaskulärer Erkrankungen ist eine zuverlässige antihyperglykämische Therapie unabdingbar. In diesem Beitrag werden die zugrunde liegenden pathophysiologischen Mechanismen von Diabetes Typ 2 kurz dargestellt und die aktuellen oralen Antidiabetika erläutert.

Abstract

Diabetes mellitus belongs to the most rapidly increasing diseases worldwide. Approximately 90–95% of these patients suffer from type 2 diabetes which is characterized by peripheral insulin resistance and an increasing loss of β-cell function. In view of the manifold complications of diabetes concerning mainly the cardiovascular system, a reliable antihyperglycemic therapy is indispensable. This report briefly depicts the underlying pathophysiological mechanisms and describes the currently available oral antidiabetic drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Brooks-Worrell B, Narla R, Palmer JP (2012) Biomarkers and immune-modulating therapies for type 2 diabetes. Trends Immunol 33:546–553

    Article  PubMed  CAS  Google Scholar 

  2. Burant CF, Viswanathan P, Marcinak J et al (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomized, double-blind, placebo-controlled trial. Lancet 379:1403–1411

    Article  PubMed  CAS  Google Scholar 

  3. Chan NN, Brain HP, Feher MD (1998) Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabetes Care 21:1659–1663

    Article  Google Scholar 

  4. Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289

    Article  PubMed  CAS  Google Scholar 

  5. European Medicine Agency (2012) European medicines agency recommends authorisation of novel treatment for type 2 diabetes. EMA/CHMP/257385/2012

  6. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596

    Article  PubMed  CAS  Google Scholar 

  7. Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517–1526

    Article  PubMed  CAS  Google Scholar 

  8. Matthaei S, Bierwirth R, Fritsche A et al (2009) Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2– Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. Diabetologie 4:32–64

    Article  Google Scholar 

  9. Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170:1191–1201

    Article  PubMed  CAS  Google Scholar 

  10. Nolan CJ, Damm P, Prentki M (2011) Type 2 diabetes across the generations: from pathophysiology to prevention and management. Lancet 378:169–181

    Article  PubMed  Google Scholar 

  11. Bundesinstitut für Arzneimittel und Medizinprodukte (Hrsg) (2012) Risikoinformation BfArm; Pioglitazon (Actos®, Competact®, Tandemact®): Leitfaden für die Verordnung und das Risikomanagement

  12. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378:182–197

    Article  PubMed  CAS  Google Scholar 

  13. Thornbury NA, Gallwitz B (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 23:479–486

    Article  Google Scholar 

  14. UK prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet 352:837–853

    Article  Google Scholar 

  15. UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352:854–865

    Google Scholar 

  16. DeFronzo RA (2009) Banting lecture. From the triumvirate to the ominious octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773–795

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Die korrespondierende Autorin gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Institut für Klinische Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland

    E. Oetjen

Authors
  1. E. Oetjen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Oetjen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oetjen, E. Orale Antidiabetika. Kardiologe 6, 467–473 (2012). https://doi.org/10.1007/s12181-012-0457-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-012-0457-0

Schlüsselwörter

Keywords

Search

Navigation